Companies /Healthcare
Johnson & Johnson
NYSE: JNJ Drug Manufacturers - General
$253.16
▼ $2.40 (−0.94%) today
Markets open · 10:50am ET

Johnson & Johnson (JNJ) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
83%
EPS beat rate
+2.42%
Avg. EPS surprise
Consecutive EPS beats
JNJ vs Market · 30-day return after each reportJNJS&P 500
0%+5%+10%−1.5%+10.5%Q1 25+7.2%+3.1%Q2 25+2.3%+1.5%Q3 25+12.8%−0.4%Q4 25−3.9%+7.7%Q1 26+5.4%+2.9%Q2 26
0%+5%+10%Q1 25Q3 25Q1 26
JNJ EPS Trend · estimate vs actualEstimateActual
$0.00$0.80$1.60$2.40$2.58$2.77Q1 25$2.68$2.77Q2 25$2.76$2.80Q3 25$2.46$2.46Q4 25$2.68$2.70Q1 26$2.85$2.90Q2 26
$0.00$0.80$1.60$2.40Q1 25Q3 25Q1 26
JNJ Revenue Trend · estimate vs actualEstimateActual
$0$7.0B$14.0B$21.0B$21.6B$21.9BQ1 25$22.9B$23.7BQ2 25$23.8B$24.0BQ3 25$24.2B$24.6BQ4 25$23.6B$24.1BQ1 26$25.1B$25.3BQ2 26
$0$7.0B$14.0B$21.0BQ1 25Q3 25Q1 26

How Often Does Johnson & Johnson Beat Earnings Estimates?

Johnson & Johnson beat EPS estimates in 5 of its last 6 reported quarters, and has beaten 2 quarters in a row.

JNJ quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 GAAP EPS of $2.27 includes $1,245M intangible asset amortization, $267M litigation-related charges, $276M restructuring charges (including $200M for new Innovative Medicine supply chain restructuring), $258M Orthopaedics separation costs, $80M acquisition/integration/divestiture costs, and $(213)M gains on securities $2.90 est. $2.85 +1.59% $25.3B est. $25.1B +0.99%
Q1 2026 $2.70 est. $2.68 +0.85% $24.1B est. $23.6B +1.89%
Q4 2025 $2.46 est. $2.46 −0.19% $24.6B est. $24.2B +1.69%
Q3 2025 $2.80 est. $2.76 +1.49% $24.0B est. $23.8B +1.00%
Q2 2025 $2.77 est. $2.68 +3.43% $23.7B est. $22.9B +3.88%
Q1 2025 $2.77 est. $2.58 +7.34% $21.9B est. $21.6B +1.48%

Figures from SEC filings and company reports. Not investment advice.